Nektar (NKTR) Gains 7.29% on June 23

Equities Staff  |

Today Nektar Therapeutics (NASDAQ: NKTR) is trading 7.29% higher.

The latest price, as of 12:05:38 est, was $4.09. Nektar has climbed $0.28 in trading today.

1,482,274 shares have exchanged hands.

As of the previous close, Nektar has a YTD change of 71.58%. The company is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Nektar visit the company profile.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

To get more information on Nektar Therapeutics and to follow the company's latest updates, you can visit the company's profile page here: Nektar Therapeutics's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content